Erratum in
    Author's view on original publication: Dietsch GN, Randall TD, Gottardo R, 
Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, 
Hershberg RM. Late Stage Cancer Patients Remain Highly Responsive to Immune 
Activation by the Selective TLR8 Agonist Motolimod (VTX–2337). Clin Cancer Res 
2015; 21(24):5445-52; PMID: ; http:/dx.doi.org/10.1158/1078-0432.CCR–15–0578.